ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Cancer

Pfizer enters pact for off-the-shelf CAR T

by Ryan Cross
April 9, 2018 | APPEARED IN VOLUME 96, ISSUE 15

South San Francisco-based Allogene Therapeutics has launched with $300 million in series A funding and a partnership with Pfizer to develop allogeneic, or off-the-shelf, CAR T-cell immunotherapies for cancer. Allogene was founded by Arie Belldegrun and David Chang, former executives of Kite Pharma, which Gilead Sciences acquired for $11.9 billion last year. Pfizer will take a 25% stake in Allogene and Allogene will get rights to 16 preclinical CAR T programs that Pfizer licensed from Cellectis and Servier. Chang tells C&EN that Allogene will recruit about 50 scientists from Pfizer this year to work on allogeneic cell therapies for cancers including solid tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment